Used in research and development of targeted therapies for thrombotic disorders and cancer. This antibody specifically binds to tissue factor (TF), a key initiator of the coagulation cascade, thereby inhibiting abnormal blood clot formation. It is employed in preclinical studies to evaluate the role of TF in pathological conditions such as sepsis, atherosclerosis, and metastatic cancer. Due to TF's overexpression in certain tumor cells and tumor-associated vasculature, this antibody serves as a tool for investigating targeted drug delivery and antibody-based cancer treatments. It also supports the development of diagnostic imaging agents for detecting TF-positive lesions. Its high specificity makes it valuable in functional assays and neutralization studies in immunology and hematology research.